{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"51.0","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received one 4 mg Baricitinib tablet administered orally QD.","id":"OG000","title":"4 mg Baricitinib Phase 3 Open-Label Addendum"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 open-label addendum participants with baseline PRO for scalp hair assessment of ≥ 3 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum","type":"SECONDARY","unitOfMeasure":"percentage of participants"}